For allergic conjunctivitis1 THE POWER TO CALM THE ITCH     BEPREVE®— FIRST-LINE, YEAR-ROUND, WITH BROAD-SPECTRUM ALLERGEN COVERAGE • 95% of BEPREVE® (bepotastine besilate ophthalmic solution) 1.5%–treated eyes (n=156 eyes) had a rapid and clinically significant reduction (>1 unit) of ocular itch (P<0.0001)3* • 90% of BEPREVE®-treated eyes (n=156 eyes) maintained a clinically significant reduction (>1 unit) of ocular itch (P<0.0001) 8 hours post dose3* To learn how patients can save up to $50 on their BEPREVE® prescription, and to order samples, please click here INDICATION BEPREVE® (bepotastine besilate ophthalmic solution) 1.5% is indicated for the treatment of itching associated with allergic conjunctivitis. IMPORTANT RISK INFORMATION BEPREVE® is contraindicated in patients with a history of hypersensitivity reactions to bepotastine or any of the other ingredients. BEPREVE® is for topical ophthalmic use only. To minimize risk of contamination, do not touch the dropper tip to any surface. Keep the bottle closed when not in use. BEPREVE® should not be used to treat contact lens–related irritation. Remove contact lenses prior to instillation of BEPREVE®. The most common adverse reaction occurring in approximately 25% of patients was a mild taste following instillation. Other adverse reactions occurring in 2%-5% of patients were eye irritation, headache, and nasopharyngitis. Please click here to view the BEPREVE® full Prescribing Information. *Study design: Two double-masked, randomized. placebo-controlled conjunctival allergen challenge (CAC) clinical studies in which patients were assigned to BEPREVE® (1.5%) or placebo. Analysis used the CAC model of allergic conjunctivitis, where severe response in ocular itching is defined as grade >3 at baseline (with a maximum score of grade 4). The primary efficacy variable was patient-evaluated ocular itching at 3, 5, and 7 minutes post challenge. Dose applied 15 minutes prior to challenge.2-5 †The data presented are derived from a subanalysis of the entire study population.2 References: 1. BEPREVE [package insert]. Irvine, CA: ISTA Pharmaceuticals, Inc; 2012. 2. Clark JC, Williams JI, Gow JA, Abelson MB, McNamara TR; for Bepotastine Besilate Ophthalmic Solutions Clinical Study Group. Bepotastine besilate ophthalmic solution 1.5% rapidly eliminates ocular itching in more severely allergic subjects in the conjunctival allergen challenge model of allergic conjunctivitis. Poster presented at: 24th Annual Eastern Allergy Conference; May 6-9, 2010; Palm Beach, FL. 3. Meier EJ, Torkildsen GL, Gow JA, McNamara TR, Gomes PJ, Williams JI; for Bepotastine Besilate Ophthalmic Solutions Study Group. Integrated phase III trials of bepotastine besilate ophthalmic solution 1.5% for ocular itching associated with allergic conjunctivitis. Allergy Asthma Proc. 2012;33:265-274. doi:10.2500/aap.2012.33.3570. 4. Data on file. Bepreve™ Integrated Summary of Efficacy. NDA 22-288. ISTA Pharmaceuticals, Inc. October 28, 2008. 5. Muñoz M, Williams JI, Gow JA, Schooley GL, McNamara TR; for Bepotastine Ophthalmic Solutions Clinical Study Group. Bepotastine besilate ophthalmic solution 1.5% provides a rapid and sustained reduction in ocular itch for severely allergic subjects following exposure to ragweed or grass pollens using the conjunctival allergen challenge (CAC) model of allergic conjunctivitis. Poster presented at: 2011 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology; November 3-8, 2011; Boston, MA. Poster P341.           ®/TM are trademarks of Bausch & Lomb Incorporated or its affiliates. ©2013 Bausch & Lomb Incorporated. US/BEP/13/0020 3/13 Bausch & Lomb Incorporated (Global Pharmaceutical Headquarters) | 7 Giralda Farms, Suite 1001, Madison, NJ 07940 1.800.323.0000 www.bausch.com